ライフサイエンスコーパス: prescription drug

1 ty, in addition to objective medical burden (prescription drugs).

2 by all local providers (excluding outpatient prescription drugs).

3 Most older adults use at least one prescription drug.

4 trations in patients poisoned with these two prescription drugs.

5 street drugs and increasing accessibility to prescription drugs.

6 and may mediate off-target effects of other prescription drugs.

7 D was associated with increased spending on prescription drugs.

8 medicine, GPCRs are targeted by about 35% of prescription drugs.

9 mechanism of action of both carcinogens and prescription drugs.

10 d participants about nonmedical injection of prescription drugs.

11 nd CYP3A enzymes metabolize more than 50% of prescription drugs.

12 versal access to care, including coverage of prescription drugs.

13 least 10 medications and 23% took at least 5 prescription drugs.

14 lling for age, sex, education, and number of prescription drugs.

15 hat herbs may have harmful interactions with prescription drugs.

16 s, including endogenous steroid hormones and prescription drugs.

17 steroid hormones and xenochemicals including prescription drugs.

18 ity from the unintentional ingestion of oral prescription drugs.

19 targets, accounting for upward of 30% of all prescription drugs.

20 exception: the concentration of spending on prescription drugs.

21 e literature on the functional mechanisms of prescription drugs.

22 c macrocycles clinically approved for use as prescription drugs.

23 spectively, in comparison to hormones (18%), prescription drugs (18%), fragrances (0.3%), and antioxi

24 ient, 33.0%; outpatient, 34.6%) care phases, prescription drugs (44.9%) were the largest cost drivers

25 5.2%) who were introduced to opioids through prescription drugs (75.0%).

26 patients (median 40 years, 22% males) used a prescription drug (81.5% vs 49.1%).

27 drug screening given a worldwide epidemic of prescription drug abuse and its devastating socioeconomi

28 ems of undertreated pain and the epidemic of prescription drug abuse have coincided, creating a need

29 g Control Policy announced its plan to fight prescription drug abuse in 2011 and unveiled the Risk Ev

30 ctors, comorbidity, depressive symptoms, and prescription drug abuse were also independently associat

31 , methamphetamines, synthetic marijuana, and prescription drug abuse, including several categorized a

32 Direct-to-consumer prescription drug ads typically fail to provide fundamen

33 DTC prescription drug advertising increased from $1.3 billio

34 in per-capita utilization of cardiovascular prescription drugs among Medicaid beneficiaries.

35 sults indicate an increase in overall use of prescription drugs among US adults between 1999-2000 and

36 nts was predictive of adult recreational and prescription drug and marijuana use and experience of se

37 Using prescription drug and medical claims data from a 5% rand

38 fects of step therapy for antidepressants on prescription drug and other medical utilization and spen

39 Our results demonstrate that non-prescription drugs and antibiotics dominated PPCP abstra

40 described in laws that broadly apply to all prescription drugs and biologic products.

41 through 2016, especially DTC advertising for prescription drugs and health services.

42 was linked with National Danish registers on prescription drugs and hospital diagnoses.

43 We compared spending for prescription drugs and other medical care 2 years before

44 cally important exogenous compounds, such as prescription drugs and therapeutic agents.

45 inpatient, outpatient, emergency department, prescription drug, and total all-cause health care expen

46 le for the metabolism of over 50% of current prescription drugs, and cyp3a4 expression is transcripti

47 epatitis, and drug-induced liver injury from prescription drugs, and herbal and dietary supplements.

48 mit direct-to-consumer advertising (DTCA) of prescription drugs, and many questions remain regarding

49 aboratory testing, the benefits and harms of prescription drugs, and some disease definitions.

50 role in the metabolism of many xenobiotics, prescription drugs, and toxins, we propose that PXR serv

51 n in the preceding week; 50% took at least 1 prescription drug; and 7% took 5 or more.

52 ubstance use disorders involving illicit and prescription drugs are a serious public health issue.

53 ted with the unintentional ingestion of oral prescription drugs are constructed for 1964 through 1992

54 Prescription drugs are instrumental to managing and prev

55 ch and development costs and prices; rather, prescription drugs are priced in the United States prima

56 urements may be helpful in identifying older prescription drugs at higher risk for price change in th

57 ut 460 child deaths from 1974, the year oral prescription drugs became subject to child-resistant pac

58 may be underused or misused in comparison to prescription drugs because of a lack of ongoing postgrad

59 Prescription drug benefit information was used to determ

60 The Medicare Part D prescription drug benefit may facilitate provision of me

61 tion about the effect of the Medicare Part D Prescription Drug Benefit on drug utilization and expend

62 ed will be critical for the affordability of prescription drug benefit programs.

63 ng the first 4 months of the Medicare Part D prescription drug benefit.

64 ts box improved U.S. consumers' knowledge of prescription drug benefits and side effects.

65 associations among cost-sharing features of prescription drug benefits and use of prescription drugs

66 ll as the difficulty in providing affordable prescription drug benefits for older Americans.

67 airs (VA) use different approaches to manage prescription drug benefits, with implications for spendi

68 n exists about the consequences of limits on prescription-drug benefits for Medicare beneficiaries.

69 costs of health care and prescription drugs, prescription-drug benefits for the elderly, the uninsure

70 d in Parts A (hospital), B (medical), and D (prescription drug) benefits, and not in Medicare Advanta

71 CT1-interacting ligands in a library of 1780 prescription drugs by combining in silico and in vitro m

72 s not known what effect the increased use of prescription drugs by enrollees in Medicare Part D has h

73 inth Revision, diagnosis for depression or a prescription drug claim for an antidepressant medication

74 inistrative data from hospital discharge and prescription drug claims databases.

75 between hospital discharge, physicians, and prescription drug claims databases.

76 We analyzed prescription drug claims for individuals prescribed PrEP

77 cohort study was conducted using medical and prescription drug claims from January 1, 2007, to Septem

78 misuse trajectories were identified for each prescription drug class.

79 ision, Clinical Modification (ICD-10-CM) and prescription drug codes used by researchers to identify

80 ly spent a much larger fraction of income on prescription drugs compared with those with employer-spo

81 Although the general prescription drug consumer price index grew at 3% per ye

82 Recent changes in US prescription drug cost sharing could affect access to th

83 ed for $2.4 billion in total Medicare part D prescription drug costs and generated the highest percen

84 ar that they wanted to discuss out-of-pocket prescription drug costs with patients but did not.

85 In response to increasing prescription drug costs, more U.S. patients and policyma

86 et competition, and taking actions to reduce prescription drug costs.

87 th care costs, ED visits, hospital days, and prescription drug costs.

88 onomic status, despite universal coverage of prescription drug costs.

89 e-based formularies in an attempt to control prescription-drug costs.

90 es were identified in adjusted out-of-pocket prescriptions drug costs between the near poor and those

91 id derivatives, a recurring motif in various prescription drugs, could be obtained via a one-pot Stau

92 The impact of Medicare prescription drug coverage (Part D) on CRN is unknown.

93 dicare Part D resulted in increased rates of prescription drug coverage across all economic strata, w

94 or status remained a risk factor for lack of prescription drug coverage after the implementation of M

95 -up of patients, targeted efforts to improve prescription drug coverage among vulnerable beneficiarie

96 the Medicare Part D drug benefit, including prescription drug coverage and risk-adjusted out-of-pock

97 ion of Part D by self-reported generosity of prescription drug coverage before 2006.

98 en born to mothers who were receiving public prescription drug coverage during pregnancy in Ontario,

99 dents of New Jersey aged 65-99 years who had prescription drug coverage either through Medicaid or th

100 Providing full prescription drug coverage for evidence-based pharmacoth

101 were continuously enrolled with medical and prescription drug coverage from 180 days before to 365 d

102 orarily stopped taking medication because of prescription drug coverage or management issues, and 18.

103 Cost-sharing in US prescription drug coverage plans for elderly persons var

104 These managers now provide prescription drug coverage to more than 100 million Amer

105 on Medicare beneficiaries who received usual prescription drug coverage under the Part D program live

106 Among respondents under age 65, prescription drug coverage was almost universal, 60% had

107 Those who received prescription drug coverage without deductibles or copaym

108 Compared with current prescription drug coverage, full coverage for post-myoca

109 and one-half were aged 65 to 90 years, with prescription drug coverage, hypertension, and at least 1

110 ohort of patients in the community with full prescription drug coverage, most patients diagnosed with

111 e myocardial infarction (AMI) survivors with prescription drug coverage, of whom 3737 were eligible f

112 nterventions to reduce copayments or improve prescription drug coverage, systems interventions to off

113 iciaries with glaucoma who previously lacked prescription drug coverage.

114 in medication adherence among patients with prescription drug coverage.

115 of reduced medication copayments or improved prescription drug coverage.

116 s over quality-of-care measures and Medicare prescription drug coverage.

117 to provide beneficiaries with near-universal prescription drug coverage.

118 adjusted for differences in supplemental and prescription-drug coverage after 65 years of age.

119 In analyses adjusted for supplemental and prescription-drug coverage, previously uninsured adults

120 Discounts required under California's prescription-drug discount program for Medicare benefici

121 percent of the pharmacies complied with the prescription-drug discount program; at only 45 percent,

122 Several states have developed prescription-drug discount programs for Medicare benefic

123 department encounters, primary care visits, prescription drug dispensations, and the provincial heal

124 003 were identified using linked data on all prescription drug dispensings, physician services, and h

125 icacious, and cost-effective to use Medicare prescription drug dollars to provide full coverage for l

126 tabases may be valuable tools for evaluating prescription drug effects on all major outcomes of clini

127 and cost trend data from the Medicare Part D Prescription Drug Event data set from 2014 to 2018 for L

128 High prescription drug expenditures are likely to continue to

129 mated $592 billion (a 38% increase over 2015 prescription drug expenditures).

130 substitution is one mechanism of curtailing prescription drug expenditures.

131 s that could be defined using both ICD-9 and prescription drug fill codes, prevalence was higher befo

132 Diseases, Ninth Revision [ICD-9] codes) and prescription drug fills.

133 nights, 0.86 for welfare benefits, 0.74 for prescription-drug fills and 0.54 for injury-insurance cl

134 Ang II type-1 receptor (AT1R) subtype, is a prescription drug for treating hypertension.

135 Metformin, a widely used prescription drug for Type 2 diabetes, has a therapeutic

136 tabolizer genotype; no nicotine for 6 weeks, prescription drugs for 4 weeks, over-the-counter drugs f

137 Evidence was mostly insufficient about prescription drugs for BPSD and about supplements for al

138 tay range: 1.5-12.0 days and 41.1-90.4% took prescription drugs for IBS-C.

139 zation Act was intended to improve access to prescription drugs for millions of seniors, by providing

140 n's rules limiting manufacturer promotion of prescription drugs for unapproved uses.

141 114 stand-alone and 2,230 Medicare Advantage prescription drug formularies, which represent all formu

142 values are reduced in individuals receiving prescription drugs found to significantly inhibit ThTR-2

143 lower cost medication to save money; bought prescription drugs from another country to save money; u

144 t discussions about the increasing prices of prescription drugs have focused on pharmacy benefit mana

145 Large-scale prescription drug importation is currently illegal, but

146 Since the introduction of the Medicare Prescription Drug Improvement and Modernization Act and

147 The Medicare Prescription Drug, Improvement, and Modernization Act (M

148 The Medicare Prescription Drug, Improvement, and Modernization Act of

149 The Medicare Prescription Drug, Improvement, and Modernization Act of

150 imated 51% of US adults reporting use of any prescription drugs in 1999-2000 and an estimated 59% rep

151 ion on direct-to-consumer advertisements for prescription drugs in 1999.

152 00 and an estimated 59% reporting use of any prescription drugs in 2011-2012 (difference, 8% [95% CI,

153 of complete information about the benefit of prescription drugs in advertisements would serve the int

154 can also explain the common use of different prescription drugs in different populations.

155 und library, and tested a selective group of prescription drugs in p-tau aggregation and cytotoxicity

156 ue of safe use of nonprescription as well as prescription drugs in patients with underlying liver dis

157 nnabinoid formulations have been approved as prescription drugs in several countries for the treatmen

158 l health conditions, smoking, and use of non-prescription drugs in the past year in both sexes, and w

159 Within each NHANES cycle, use of prescription drugs in the prior 30 days was assessed ove

160 The increasing cost of prescription drugs in the United States has become a sou

161 hysicians to address the escalating costs of prescription drugs in the United States.

162 nal spending for the 150 top-selling branded prescription drugs in the US in 2020 as identified from

163 llicit drug use, including nonmedical use of prescription drugs, in children, adolescents, and young

164 NET is a known target for a variety of prescription drugs, including antidepressants and psycho

165 CI, 29.3%-29.3%) and less likely to utilize prescription drugs, including opioids (41.4%; 99% CI, 41

166 The prevalence of polypharmacy (use of >/=5 prescription drugs) increased from an estimated 8.2% in

167 gests that direct-to-consumer advertising of prescription drugs increases pharmaceutical sales and bo

168 sts exceeded adjustments for medical care or prescription drug inflation rates.

169 After adjusting for medical care or prescription drug inflation, 2022 payments per claim inc

170 rmaceutical assistance program that provides prescription drug insurance for elderly persons.

171 Potential herb-prescription drug interactions are not just limited to S

172 The increasing price of prescription drugs is an ongoing concern for Medicare an

173 Spending on prescription drugs is the fastest growing component of t

174 evidence indicates that gabapentin (GBP), a prescription drug, is prone to misuse, abuse, withdrawal

175 hanger of amino acids, thyroid hormones, and prescription drugs--is highly expressed in the blood-bra

176 Generic prescription drugs made by different manufacturers may v

177 s, beginning in the 1940s when growth in the prescription drug market fueled industry interest in und

178 The prescription drug market in the United States relies on

179 gents are the fastest-growing segment of the prescription drug market.

180 nd updated to achieve success in the current prescription drug market.

181 gists and industry employees relative to the Prescription Drug Marketing Act or the False Claims Act

182 m), each pled guilty to one violation of the Prescription Drug Marketing Act, settled claims related

183 ge, male sex, IADL disability, and number of prescription drugs measured at baseline were significant

184 th, use of marijuana and recreational drugs, prescription drug misuse (adult gender expression only),

185 five trajectories was the age when past-year prescription drug misuse high frequency peaked: rare or

186 es are heterogeneous, and any high-frequency prescription drug misuse is a strong risk factor for dev

187 Prescription drug misuse is most prevalent during young

188 pread implementation of illicit drug use and prescription drug misuse screening and brief interventio

189 Prescription drug misuse trajectories are heterogeneous,

190 We aimed to identify prescription drug misuse trajectories for three drug cla

191 Prescription drug misuse trajectories were all associate

192 Five prescription drug misuse trajectories were identified an

193 Similar prescription drug misuse trajectories were identified fo

194 d identity factors associated with high-risk prescription drug misuse trajectories.

195 ders during adulthood, especially later-peak prescription drug misuse trajectories.

196 rs associated with the high-risk latest peak prescription drug misuse trajectory included high school

197 equent alcohol use, frequent binge drinking, prescription drug misuse, and over-the-counter drug misu

198 brief intervention for illicit drug use and prescription drug misuse, based in part on evidence of e

199 king, cigarette smoking, marijuana use, poly-prescription drug misuse, white race, and not completing

200 s first identification, to our knowledge, of prescription drugs modifying the regulation of cathepsin

201 vel data derived from California's statewide prescription drug monitoring program (PDMP) and county-l

202 f adolescents reporting IDU before and after prescription drug monitoring program (PDMP) mandates wer

203 In 2011, Florida established a prescription drug monitoring program and adopted new reg

204 tests, monitoring pill counts, and reviewing prescription drug monitoring program data, when availabl

205 every 3 months or more frequently and review prescription drug monitoring program data, when availabl

206 ristics, and indicators of implementation of prescription drug monitoring program use mandates.

207 onal study using data from medical examiner, prescription drug monitoring program, and opiate treatme

208 Use of urine drug tests, prescription drug monitoring programmes and close observ

209 ordinated care possible, states have created prescription drug monitoring programs to collect records

210 ion with adjustment for age, marital status, prescription drug monitoring programs, and use of other

211 Other resources, such as state-run prescription drug monitoring programs, are also availabl

212 thmic use of validated pain screening tools, prescription drug monitoring programs, urine drug screen

213 n 120 mg did not decline after adoption of a prescription-drug monitoring program (0.27 percentage po

214 012) and an original data set of laws (e.g., prescription-drug monitoring programs), we examined the

215 of the FPL) and (2) cost-sharing levels for prescription drugs, office visits, and emergency departm

216 groups, respectively), patients with active prescription drug orders for metformin (134 [58.26] vs 1

217 Communication about prescription drugs ought to be a paragon of public scien

218 trols for changes in the consumption of oral prescription drugs over time and for long-term safety tr

219 nd >= 11) and presence of polypharmacy (>= 5 prescription drugs per day).

220 nrollment versus nonenrollment in Medicare's prescription drug plan (Part D) is associated with bette

221 the source population of Medicare Advantage Prescription Drug plan beneficiaries, 8% entered the cov

222 This study uses Medicare Part D prescription drug plan formulary files to characterize c

223 We used the Medicare July 2014 Prescription Drug Plan Formulary, Pharmacy Network, and

224 ne or pioglitazone through a Medicare Part D prescription drug plan from July 2006-June 2009 and who

225 rs participating in a Medicare Advantage and prescription drug plan operating in 4 US states.

226 re beneficiaries who enrolled in a state-run prescription drug plan that fully covered NSAIDs and cox

227 ion drug plans (PDPs) and Medicare Advantage Prescription Drug plans (MA-PDs) were followed for at le

228 Beneficiaries with stand-alone prescription drug plans (PDPs) and Medicare Advantage Pr

229 Prescription drugs play an important part in treating an

230 lopment, an expert in regulatory science and prescription drug policy and a prominent patient advocat

231 g in the biological samples (5.6%), although prescription drugs (prescription pain pills, sedatives,

232 for voters were the costs of health care and prescription drugs, prescription-drug benefits for the e

233 olicy changes enabling Medicare to negotiate prescription drug prices could decrease costs to Medicar

234 or Medicare & Medicaid Services to negotiate prescription drug prices for Medicare may improve drug a

235 All 30-day prescription drug prices offered by MCCPDC generated cos

236 eliable, timely, and relevant information on prescription drug pricing for physicians and patients.

237 ected by > 80% of participants: cancer care, prescription drugs, primary care, home care, palliative

238 ce programs improve patient access to costly prescription drugs, recent federal investigations have r

239 lthough objective data are used routinely in prescription drug recommendations, it is unclear how ref

240 ts (SEER)-Medicare linked database including prescription drug records.

241 l patient registry, cause of death registry, prescription drug registry, and education and income reg

242 ociated with an annual reduction in the oral prescription drug-related mortality rate of 1.40 (95% co

243 elationship between the availability of free prescription drug samples and dermatologists' prescribin

244 For problem use of illicit and prescription drugs, sensitivity ranged from 0.82 (CI, 0.

245 rating SEs extracted from package inserts of prescription drugs, SEs extracted from FDA Adverse Event

246 mbia (2004-2011), which include health care, prescription drugs, sociodemographic, and mortality info

247 ocuments, and the Medicare Part B and Part D prescription drug spending dashboards were used to deter

248 For each 10% increase in cost sharing, prescription drug spending decreases by 2% to 6%, depend

249 e-source drugs and 11% of total Medicare net prescription drug spending in 2020.

250 Per capita prescription drug spending in the United States exceeds

251 , have been the primary source of increasing prescription drug spending in the US.

252 valent to brand-name drugs, can help contain prescription drug spending.

253 s to the patient and offset a decline in OOP prescription drug spending.

254 us (HIV) are a major contributor to Medicaid prescription drug spending.

255 talyzes the covalent modification of certain prescription drugs such as the commonly used steroid, pr

256 Our comprehensive analysis of prescription drugs suggests that several marketed drugs

257 edication error or evaluate patients' actual prescription drug-taking behaviors.

258 , the United States often pays more for some prescription drugs than other developed countries, and t

259 Here, we identify prescription drugs that bind NET, using virtual ligand s

260 ffer chemically from another-and, unlike for prescription drugs, there are no databases linking herb

261 gh reference pricing may reduce the costs of prescription drugs, there is concern that patients may s

262 ending on direct-to-consumer advertising for prescription drugs tripled between 1996 and 2000, when i

263 ources of regional variation in spending for prescription drugs under Medicare Part D are poorly unde

264 cipants after adjusting for age, gender, and prescription drug use (SH group with 5 or more episodes

265 calculated prevalence ratios (PRs) comparing prescription drug use 36 months after RYGB/index date wi

266 Evaluation of prescription drug use among elderly persons by type of h

267 ge 18 years had the highest adjusted odds of prescription drug use and PDM in adulthood (4-5 symptoms

268 ive survey, significant increases in overall prescription drug use and polypharmacy were observed.

269 A little is known about the prescription drug use before and after RYGB surgery.

270 might be accurate for timing first-trimester prescription drug use in automated databases.

271 The prevalence of prescription drug use increased in the majority of, but

272 lso reported positive outcomes in nonmedical prescription drug use occasions.

273 methods of data collection to understand the prescription drug use problem.

274 It is important to document patterns of prescription drug use to inform both clinical practice a

275 Prescription drug use was estimated for lipid-modifying

276 Temporal trends in prescription drug use were evaluated using nationally re

277 not differ significantly in inpatient care, prescription drug use, or number of emergency department

278 sex, calendar time, hospital diagnoses, and prescription drug use.

279 icare data for 4.7 million beneficiaries for prescription-drug use and expenditures overall and in th

280 res of prescription drug benefits and use of prescription drugs, use of nonpharmaceutical services, a

281 ental ill health outcome) or initiation of a prescription drug used to treat mental ill health, and t

282 The Prescription Drug User Fee Act (PDUFA) imposes deadlines

283 The amount of Prescription Drug User Fee Act fees collected from indus

284 The upcoming reauthorization of the Prescription Drug User Fee Act focuses on improving the

285 Prescription drug user fee funding expanded from new dru

286 Among prescription drug users, 16% also took an herbal/supplem

287 CIPANTS: This cross-sectional study analyzed prescription drug utilization and cost trend data from t

288 Cash prices for prescription drugs vary widely in the United States.

289 In 2013, per capita spending on prescription drugs was $858 compared with an average of

290 ending for promotional purposes and sales of prescription drugs, we examined industrywide trends for

291 , while being employed and nonmedical use of prescription drugs were associated with binge drinking c

292 For both men and women and at all ages, prescription drugs were involved in more deaths than wer

293 to treat health problems without doctors or prescription drugs were more likely to prefer an annual

294 e in cells stably expressing MATE1, over 900 prescription drugs were screened and 84 potential MATE1

295 ly on other countries as sources of imported prescription drugs: whether the safety of the product ca

296 lighting that-unlike clinical biomarkers and prescription drugs, which may individually work better i

297 ility that direct-to-consumer advertising of prescription drugs will result in inappropriate prescrib

298 suffer from dry mouth as a result of taking prescription drugs, with an apparent concomitant increas

299 Although the year 2001 did not see any prescription drugs withdrawn because of drug-induced liv

300 al diversion, defined as a death involving a prescription drug without a documented prescription and